The co-occurrence of BCR::ABL1 kinase domain mutations and cancer gene mutations in a high proportion of resistant patients indicates that we should not consider resistance as either BCR::ABL1-dependent or BCR::ABL1-independent. This evidence concerns the gene BCR and cancer.